Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population
Table 2
Genotype distributions and allele frequencies of examined SNPs in UBC cases.
SNP ID
Cases
Controls
( value
( value OR (95% CI); ( value
(%)
(%)
GSTM1:
“+/+”
28 (53.8)
64 (61.5)
0.8
0.8
“−/−”
24 (46.2)
40 (38.5)
0.8
“+”
56 (0.54)
128 (0.62)
1.4 (0.9–2.2); 1.3
“−”
48 (0.46)
80 (0.38)
GSTT1:
“+/+”
46 (88.5)
96 (92.3)
0.6
0.6
“−/−”
6 (11.5)
8 (7.7)
0.6
“+”
92 (0.88)
192 (0.92)
1.6 (0.7–3.4); 1.1
“−”
12 (0.12)
16 (0.08)
CYP1A1 T6235C (rs4646903):
TT
34 (65.4)
60 (57.7)
0.8
1.7
TC
16 (30.8)
42 (40.4)
1.4
CC
2 (3.8)
2 (1.9)
0.5
T
84 (0.81)
162 (0.78)
0.8 (0.5–1.5); 0.6
C
20 (0.19)
46 (0.22)
CYP1A1 A4889G (rs1048943):
AA
46 (88.5)
92 (88.5)
0.0
4.5
AG
4 (30.8)
12 (11.5)
8.7
GG
2 (26.9)
0 (0.0)
30.5 (<0.0001
A
96 (0.92)
196 (0.94)
1.4 (0.5–3.4); 0.7
G
8 (0.08)
12 (0.06)
TP53 Pro72Arg (rs1042522):
Pro/Pro
16 (30.8)
16 (15.4)
5.0
5.6
Pro/Arg
22 (42.3)
60 (57.7)
3.3
Arg/Arg
14 (26.9)
28 (26.9)
0.0
Pro
54 (0.52)
92 (0.44)
0.7 (0.5–1.2); 1.3
Arg
50 (0.48)
116 (0.56)
MTHFR C677T (rs1801133):
CC
33 (63.5)
88 (84.6)
8.8
14.4
CT
14 (26.9)
16 (15.4)
2.9
TT
5 (9.6)
0 (0.0)
10.2
C
80 (0.77)
192 (0.88)
3.6 (1.8–7.1); 3.7
T
24 (0.23)
16 (0.12)
MTRR A66G (rs1801394):
AA
0 (0.0)
40 (38.5)
26.8 (<0.0001
35.6
AG
32 (61.5)
54 (51.9)
1.3
GG
20 (38.5)
10 (9.6)
18.5 (<0.0001
A
32 (0.31)
134 (0.64)
4.1 (2.5–6.7); 5.5 (<0.0001
G
72 (0.69)
74 (0.36)
“+”: present allele; “−”: null allele; “−,−”: homozygous null genotype; “+,+”: homozygous present genotype; OR: odds ratio; CI: confidence interval. difference between two similar genotypes in cases and controls. difference between genotypes of a specific SNP in cases compared with controls. of allele frequencies of a specific SNP.
